Jump to content
RemedySpot.com

Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic.

Rate this topic


Recommended Posts

Posted

J Viral Hepat. 2010 Dec 8. doi: 10.1111/j.1365-2893.2010.01382.x. [Epub ahead of

print]

Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to

respond to a diverse local epidemic.

Gish RG, SL.

Division of GI Hepatology, University of California, San Diego, CA, USA Division

of Hepatology, San Francisco Center for Liver Disease, San Francisco, CA, USA

Department of Medicine Department of Transplantation, California Pacific Medical

Center and Research Institute, and Sutter Pacific Medical Foundation, San

Francisco, CA, USA Liver Immunology Laboratory, California Pacific Medical

Center and Research Institute and Sutter Pacific Medical Foundation, San

Francisco, CA, USA.

Abstract

Summary.  Although chronic hepatitis B (CHB) affects approximately 2 million

United States residents, there is no systematic screening of at-risk

individuals, and most remain unaware of their hepatitis B virus (HBV) infection.

Unmonitored and untreated, CHB results in a 25-30% risk of death from liver

cancer and/or cirrhosis, inflicting an increasing healthcare burden in

high-prevalence regions. Despite high prevalence in immigrant Asians and Pacific

Islanders, among whom CHB is a leading cause of death, community and healthcare

provider awareness remains low. Because safe and effective vaccines and

effective antiviral treatments exist, there is an urgent need for integrated

programmes that identify, follow and treat people with existing CHB, while

vaccinating the susceptible. We describe an extant San Francisco programme that

integrates culturally targeted, population-based, HBV screening, vaccination or

reassurance, management and research. After screening over 3000 at-risk

individuals, we here review our operational and practical experience and

describe a simple, rationally designed model that could be successfully used to

greatly improve the current approach to hepatitis B while ultimately reducing

the related healthcare costs, especially in the high-risk populations, which are

currently underserved.

© 2010 Blackwell Publishing Ltd.

PMID: 21143342 [PubMed - as supplied by publisher]

Posted

J Viral Hepat. 2010 Dec 8. doi: 10.1111/j.1365-2893.2010.01382.x. [Epub ahead of

print]

Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to

respond to a diverse local epidemic.

Gish RG, SL.

Division of GI Hepatology, University of California, San Diego, CA, USA Division

of Hepatology, San Francisco Center for Liver Disease, San Francisco, CA, USA

Department of Medicine Department of Transplantation, California Pacific Medical

Center and Research Institute, and Sutter Pacific Medical Foundation, San

Francisco, CA, USA Liver Immunology Laboratory, California Pacific Medical

Center and Research Institute and Sutter Pacific Medical Foundation, San

Francisco, CA, USA.

Abstract

Summary.  Although chronic hepatitis B (CHB) affects approximately 2 million

United States residents, there is no systematic screening of at-risk

individuals, and most remain unaware of their hepatitis B virus (HBV) infection.

Unmonitored and untreated, CHB results in a 25-30% risk of death from liver

cancer and/or cirrhosis, inflicting an increasing healthcare burden in

high-prevalence regions. Despite high prevalence in immigrant Asians and Pacific

Islanders, among whom CHB is a leading cause of death, community and healthcare

provider awareness remains low. Because safe and effective vaccines and

effective antiviral treatments exist, there is an urgent need for integrated

programmes that identify, follow and treat people with existing CHB, while

vaccinating the susceptible. We describe an extant San Francisco programme that

integrates culturally targeted, population-based, HBV screening, vaccination or

reassurance, management and research. After screening over 3000 at-risk

individuals, we here review our operational and practical experience and

describe a simple, rationally designed model that could be successfully used to

greatly improve the current approach to hepatitis B while ultimately reducing

the related healthcare costs, especially in the high-risk populations, which are

currently underserved.

© 2010 Blackwell Publishing Ltd.

PMID: 21143342 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...